Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer After Primary Treatment with Curative Intent-Impact of Delayed Imaging

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jun 24

PMID 35743385

Authors

Jolanta Kunikowska

Kacper Pelka

Omar Tayara

Leszek Krolicki

Affiliations

Soon will be listed here.

Abstract

The presence of prostate-specific membrane antigen (PSMA) on prostate cancer cells and its metastases allows its use in diagnostics using PET/CT. The aim of this study was to evaluate the usefulness of delayed phase images in the Ga-68-PSMA-11 PET/CT. Methods: 108 patients with prostate cancer (median age: 68.5 years, range: 49−83) were referred for Ga-68-PSMA-11 PET/CT due to biochemical relapse (PSA (prostate-specific antigen) (3.2 ± 5.4 ng/mL). Examinations were performed at 60 min, with an additional delayed phase of the pelvis region at 120−180 min. Results: The Ga-68-PSMA-11 PET/CT showed lesions in 86/108 (80%) patients; detection rate depending on the PSA level: 0.2 < PSA < 0.5 ng/mL vs. 0.5 ≤ PSA < 1.0 ng/mL vs. 1.0 ≤ PSA < 2.0 ng/mL vs. PSA ≥ 2.0 ng/mL was 56% (standard vs. delay: 56 vs. 56%) vs. 60% (52 vs. 60%) vs. 87% (83 vs. 87%) vs. 82% (77 vs. 82%) of patients, respectively. The delayed phase had an impact on the treatment in 14/86 patients (16%) (p < 0.05): 7 pts increased uptake was seen only after 60 min, which was interpreted as physiological or inflammatory accumulation; the delayed image showed increased accumulation in 7 patients only: 4 in regional lymph nodes, 1 in local recurrence, and 2 patients with local recurrence showed additional foci. Conclusions: Delayed phase of Ga-68-PSMA-11 PET/CT has an impact on treatment management in 16% of patients.

Citing Articles

High Detection Rates for Prostate-specific Membrane Antigen-avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography.

Thomas S, Callahan J, Conway P, Moon D, Morgan H, Ingbritsen J Eur Urol Open Sci. 2024; 71:49-56.

PMID: 39720335 PMC: 11667164. DOI: 10.1016/j.euros.2024.11.008.

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.

Tomiyoshi K, Wilson L, Mourtada F, Mourtada J, Namiki Y, Kamata W Pharmaceutics. 2024; 16(11).

PMID: 39598580 PMC: 11597032. DOI: 10.3390/pharmaceutics16111458.

Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma.

Kohlbrenner R, Wu X, Nguyen H, Cooperberg M, Chakravarty T, Carroll P Radiology. 2024; 312(2):e232544.

PMID: 39136560 PMC: 11366670. DOI: 10.1148/radiol.232544.

Diagnostic value of dual-time point Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer.

Xiao L, Su M, Li Y Abdom Radiol (NY). 2024; 49(9):3214-3219.

PMID: 38546825 DOI: 10.1007/s00261-024-04269-w.

The superior detection rate of total-body [Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.

Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W Eur J Nucl Med Mol Imaging. 2024; 51(8):2484-2494.

PMID: 38514483 DOI: 10.1007/s00259-024-06674-1.

References

Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S . The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2019; 47(3):642-651. DOI: 10.1007/s00259-019-04552-9. View

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K . Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. Eur Urol Focus. 2018; 5(6):1007-1013. DOI: 10.1016/j.euf.2018.02.015. View

Rajasekaran A, Anilkumar G, Christiansen J . Is prostate-specific membrane antigen a multifunctional protein?. Am J Physiol Cell Physiol. 2005; 288(5):C975-81. DOI: 10.1152/ajpcell.00506.2004. View

Tian A, Lin R, Yu J, Zhang F, Zheng Q, Yuan X . The differential diagnostic value of dual-phase F-DCFPyL PET/CT in prostate carcinoma. Prostate Cancer Prostatic Dis. 2022; 25(2):351-358. PMC: 9184273. DOI: 10.1038/s41391-022-00534-5. View

Stephenson A, Scardino P, Eastham J, Bianco Jr F, Dotan Z, Fearn P . Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006; 98(10):715-7. PMC: 2242430. DOI: 10.1093/jnci/djj190. View

Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X . Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2018; 103(5):1061-1067. DOI: 10.1016/j.ijrobp.2018.12.020. View

Derlin T, Weiberg D, von Klot C, Wester H, Henkenberens C, Ross T . Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016; 26(12):4345-4353. DOI: 10.1007/s00330-016-4308-4. View

Hoffmann M, Buchholz H, Wieler H, Rosar F, Miederer M, Fischer N . Dual-Time Point [Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. Cancers (Basel). 2020; 12(10). PMC: 7600341. DOI: 10.3390/cancers12102788. View

Hull G, Rabbani F, Abbas F, Wheeler T, Kattan M, Scardino P . Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167(2 Pt 1):528-34. DOI: 10.1016/S0022-5347(01)69079-7. View

10.

Zlatopolskiy B, Endepols H, Krapf P, Guliyev M, Urusova E, Richarz R . Discovery of F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. J Nucl Med. 2018; 60(6):817-823. PMC: 6581226. DOI: 10.2967/jnumed.118.218495. View

11.

De Bleser E, Jereczek-Fossa B, Pasquier D, Zilli T, van As N, Siva S . Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol. 2019; 76(6):732-739. DOI: 10.1016/j.eururo.2019.07.009. View

12.

Wondergem M, van der Zant F, Knol R, Lazarenko S, Pruim J, de Jong I . F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med. 2017; 58(11):1797-1804. DOI: 10.2967/jnumed.117.192658. View

13.

Kunikowska J, Kujda S, Krolicki L . 68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?. Clin Nucl Med. 2020; 45(4):e213-e214. DOI: 10.1097/RLU.0000000000002966. View

14.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

15.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F . Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2018; 46(1):31-39. DOI: 10.1007/s00259-018-4189-7. View

16.

Rischke H, Schultze-Seemann W, Wieser G, Kronig M, Drendel V, Stegmaier P . Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2014; 191(4):310-20. DOI: 10.1007/s00066-014-0763-5. View

17.

Opoka L, Kunikowska J, Podgajny Z, Szolkowska M, Blasinska-Przerwa K, Burakowska B . Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions - own experience. Pneumonol Alergol Pol. 2014; 82(3):198-205. DOI: 10.5603/PiAP.2014.0027. View

18.

Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S . Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2013; 65(6):1034-43. DOI: 10.1016/j.eururo.2013.08.013. View

19.

Hohberg M, Kobe C, Tager P, Hammes J, Schmidt M, Dietlein F . Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2018; 21(3):558-566. DOI: 10.1007/s11307-018-1263-2. View

20.

Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts J . 3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. J Nucl Med. 2019; 61(6):866-872. DOI: 10.2967/jnumed.119.235028. View